Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis

The first-in-class, once-daily Bruton tyrosine kinase (BTK) inhibitor ibrutinib is one of the preferred standards of care for patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), which has a median overall survival (OS) of 4-5 years.[1][1]–[3][2] We previously reported a pooled